Moberg Pharma completes divestment of three brands for $10.4 million

STOCKHOLM, April 4th, 2016. Moberg Pharma AB (OMX: MOB) announces that the
company has completed the divestment of the Jointflex, Fergon and Vanquish
brands to Strides Pharma Inc. for a total consideration of $10.4 million,
whereof $0.4 million comprises inventory value.
Moberg Pharma’s strategy is to build value through profitable growth of
strategic brands, increasing the value of pipeline assets and acquisitions.
Completing the divestment of the three brands enables Moberg Pharma to focus on
its core business.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8:30 am (CET) on April 4th, 2016.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 707 35 71 35, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets)
is a leading OTC treatment of nail disorders in the U.S., Canada and several EU
markets and is currently being launched in Southeast Asia. The company is
growing organically as well as through acquisitions. Internal development
programs focuses on innovative drug delivery of proven compounds and include two
clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral
mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the
company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic
Exchange Stockholm (OMX: MOB).